Global NASH congress

Watch now

ABSTRACT

Using the power of the world’s largest proteomic platform coupled with machine learning , clinical samples and known biopsy results were used to build proteomic models capable of staging steatosis, inflammation, ballooning and fibrosis, and diagnosing at-risk NASH. These models exhibit competitive performance vs. existing standard methods. Use-cases in drug development include a participant rule-out prior to biopsy and precision demonstration of pharmacodynamic mechanistic impacts on individual liver components with multiple longitudinal measurements. Combination of the liquid liver biopsy with other proteomic tests on the same platform can expand the assessment of drug impact to include changes in cardiovascular risk, insulin resistance, kidney function and body composition. This will result in smaller, faster and more comprehensive clinical trials in the future.

Highlights:

  • Proteomic models capable of staging and diagnosing conditions for “at-risk” NASH
  • Assessment of pharmacodynamic mechanisms over time
  • Simultaneous drug impact assessment of multiple biological metrics

stephen

Stephen A. Williams, MD, PhD

Chief Medical Officer, SomaLogic

Steve Williams, MD, Ph.D, practiced medicine for over a decade at Charing Cross Hospital before joining Pfizer, where he became the VP and Worldwide Head of Clinical Technology. Since 2009 he has been the Chief Medical Officer at SomaLogic, where his focus has been on developing clinical tests using proteomic signatures.

Share with colleagues

More webinars

WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes

In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.

Learn more

WebinarHarnessing AI and proteomics for glioblastoma

The development and advancement of aptamer technology opens vast possibilities for unlocking the biocomplexity available within proteomics. Learn more about the powerful tools that are enabling the discovery and validation of clinically relevant biomarkers and accelerating research.

Learn more

WebinarMapping the human mucosal immune response to respiratory viruses

Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.

Learn more